![](https://library.celltelligence.com/wp-content/uploads/2020/05/Autolus-Clinical-Trails.png)
$0
Updated AUTO3 Ph1/2 ALEXANDER Results; ESMO 2020 Investor Call Summary
On Friday, September 18, Autolus held an investor call (press release / presentation), highlighting updated clinical data from the AUTO3 (CD19/22 dual CAR-T) Ph1/2 ALEXANDER study in ≥3L DLBCL. The data was also presented at ESMO (E.Tholouli et al, Sep 2020). Below, Celltelligence provides thoughts on the significance of this data, and particularly how it compares to competitor autologous CD19 CAR-Ts from Novartis (Kymriah), Gilead (Yescarta), and BMS (liso-cel).